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Intensivists are regularly confronted with the question of gastrointestinal bleeding. To date, the latest international
recommendations regarding prevention and treatment for gastrointestinal bleeding lack a specific approach to the
critically ill patients. We present recommendations for management by the intensivist of gastrointestinal bleeding in
adults and children, developed with the GRADE system by an experts group of the French-Language Society of
Intensive Care (Société de Réanimation de Langue Française (SRLF), with the participation of the French Language
Group of Paediatric Intensive Care and Emergencies (GFRUP), the French Society of Emergency Medicine (SFMU),
the French Society of Gastroenterology (SNFGE), and the French Society of Digestive Endoscopy (SFED). The
recommendations cover five fields of application: management of gastrointestinal bleeding before endoscopic
diagnosis, treatment of upper gastrointestinal bleeding unrelated to portal hypertension, treatment of upper
gastrointestinal bleeding related to portal hypertension, management of presumed lower gastrointestinal bleeding,
and prevention of upper gastrointestinal bleeding in intensive care.
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Introduction
Intensivists are regularly confronted with the question of
gastrointestinal (GI) bleeding. They notably need to man-
age acute GI bleeding, a frequent and severe condition [1],
the mortality of which has probably not changed for 20
years [1] but could be reduced through recent diagnostic
and therapeutic advances [2]. They also should define, for
each patient admitted to intensive care, how to prevent
upper GI bleeding related to “stress ulceration”. a now un-
common complication [3], but for which drug prophylaxis
is widely used [4] and often involves proton pump inhibi-
tors (PPIs) [4]. Because the latest international recommen-
dations for the management of acute nonvariceal upper
GI bleeding [2] or for GI bleeding related to portal hyper-
tension [5] lack a specific approach to severe forms, and
because the French consensus conference on prevention
of “stress-related” upper GI bleeding in intensive care was
nearly 25 years ago [6], we decided to draw up these
recommendations (Table 1).* Correspondence: david.osman@bct.aphp.fr
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The SRLF brought together a group of experts represent-
ing the various disciplines involved in the management of
severe GI bleeding (critical care, hepatogastroenterology,
emergency care, radiology, surgery, pediatrics) to draw up
these recommendations. The organizing committee and
the coordinator first defined the questions to be considered
and designated the experts responsible for each question.
Using the GRADE system (Grading of Recommendations,
Assessment, Development and Evaluation) [7,8], the litera-
ture was analyzed and recommendations were formulated.
A level of proof was defined for each literature reference
according to the type of study, and could be reevaluated
taking into account the methodological quality of the
study. The literature references common to each assess-
ment criterion were then grouped. An overall level of proof
was determined for each assessment criterion taking into
account the levels of proof of each literature reference, the
consistency of the results between the different studies,
the cost-effectiveness analysis, the directness of the evi-
dence, etc. A “strong” level of proof enabled a “strong”
recommendation (“must be done,” “must not be done. . .”).
A “moderate,” “weak,” or “very weak” level of proof
resulted in a “conditional” recommendation (“shouldan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Recommendations for management by the intensivist of gastrointestinal bleeding
Area 1: Management of GI bleeding before endoscopic diagnosis 11 In children, in massive hematochezia and/or with hemodynamic
consequences, and when GI endoscopic findings are normal,
an emergency scintigraphy to search for a Meckel’s diverticulum
should be used and/or a surgical exploration (McBurney’s
incision or coelioscopy) (strong agreement)
5 In the presence of stigmata associated with a high risk
of rebleeding (Forrest type Ia, Ib, IIa, IIb), PPI treatment
should be continued at “high” doses for 72 h
(strong agreement)
1 Nasogastric intubation may help confirm, but cannot discount,
suspected upper GI bleeding (strong agreement)
12 Vasoactive treatment (terlipressin or somatostatin
derivative) should be administered as soon as possible
when portal hypertension is the suspected cause if
GI bleeding (strong agreement)
6 Second-look EGD should not be done routinely (strong
agreement)
2 Suspected rupture of esophageal/gastric varices probably
does not contraindicate nasogastric intubation
(strong agreement)
13 In a patient already treated with noradrenaline, specific
vasoactive treatment of the splanchnic area (terlipressin,
somatostatin, somatostatin derivative) should probably be
administered when portal hypertension is the suspected
cause of GI bleeding (expert opinion, weak agreement).
7 Second-look EGD should probably be done when a
high-risk stigmata has been observed(weak agreement)
3 To ensure emptying of the stomach content before EGD,
intravenous erythromycin should be administered at a
dose of 250 mg (5 mg/kg in children), in the absence
of contraindications (strong agreement)
14 Specific vasoactive treatment of the splanchnic area
(terlipressin, somatostatin, somatostatin derivative) should
probably not be administered when portal hypertension
is not the suspected cause of GI bleeding (weak agreement)
8 Patients with ulcer bleeding should not be treated
with H2 receptor antagonists (strong agreement)
4 If a nasogastric tube has been inserted, gastric lavage
to empty the stomach is an alternative to administration
of erythromycin (weak agreement)
15 In GI bleeding potentially caused by ulcers, PPI treatment
should be started without waiting for endoscopic
diagnosis (weak agreement)
9 In adults, in case of Forrest type Ia and Ib, first-
intention selective arterial embolization by
interventional radiology should probably be used
following failure of endoscopic therapy (weak
agreement)
5 In adults, the Rockall score and the Glasgow-Blatchford
bleeding score can probably help to identify patients
at high risk of morbidity and mortality and to refer
them to an intensive care unit (strong agreement)
16 In GI bleeding potentially caused by ulcers, high-dose
PPI treatment should probably be administered
(weak agreement)
10 In adults, in case of Forrest type Ia and Ib and
catastrophic bleeding, first-intention surgical
hemostasis should probably be used following failure
of endoscopic therapy if local conditions do not allow
arterial embolization(strong agreement)
6 EGD should be done in the 24 h following the admission
of the patient with suspected upper GI bleeding
(strong agreement)
Area 2: Treatment of upper GI bleeding unrelated to
portal hypertension
11 Biopsy screening for Helicobacter pylori infection can
be performed during the first EGD for GI bleeding
without worsening the bleeding (strong agreement)
7 EGD should be probably done in the b12 h following
the admission of the patient with suspected
esophageal/gastric variceal bleeding (strong agreement)
1 In the presence of stigmata associated with a low risk
of rebleeding (Forrest type IIc and III), endoscopic
hemostasis should not be used (strong agreement)
12 There is probably no advantage to emergency
treatment of Helicobacter pylori infection in the case
of GI ulcer bleeding (strong agreement)
8 EGD should be probably done as soon as possible,
and once the patient is resuscitated, when active
upper GI bleeding is suspected (strong agreement)
2 In the presence of stigmata associated with a low risk
of rebleeding (Forrest type IIc and III), PPI treatment
at “standard” doses should be continued (strong agreement)
13 Aspirin antiplatelet therapy should probably be
maintained in the case of GI ulcer bleeding until
consultation with specialists (weak agreement)
9 In massive hematochezia and/or hemodynamic
consequences, an EGD should be performed as soon
as possible (strong agreement)
3 In the presence of stigmata associated with a high risk of
rebleeding (Forrest type Ia, Ib, IIa), endoscopic hemostasis
should be performed (strong agreement)
14 In dual antiplatelet therapy, clopidogrel should
probably be stopped in the case of ulcer bleeding
until consultation with specialists (strong agreement)
10 In adults, in massive hematochezia and/or with hemodynamic
consequences, a CT angiography should be performed in
emergency, if EGD is not rapidly available and/or if an
aortoenteric fistula is suspected (strong agreement)
4 In the presence of an adherent clot (Forrest type IIb),
endoscopic hemostasis is possible when the clot is
small (strong agreement)





















Table 1 Recommendations for management by the intensivist of gastrointestinal bleeding (Continued)
1 Endoscopic therapy of bleeding esophageal/gastric
varices should be done during initial EGD (strong
agreement)
13 Blood transfusion in most patients should probably target a
hemoglobin concentration of 7 to 8 g/dL (strong agreement)
5 When lower GI bleeding is massive, surgical
hemostasis should be proposed in case of arterial
embolization or colonoscopy failure or rebleeding
(strong agreement)
2 Endoscopic therapy of bleeding esophageal varices
is based on band ligation. Sclerotherapy is an
alternative in the very young child (strong agreement)
14 In GI bleeding in patients with cirrhosis, there is probably no
indication for administration of fresh-frozen plasma with the
objective to correct a coagulopathy (strong agreement)
6 When lower GI bleeding is catastrophic, surgical
hemostasis should be performed if arterial
embolization is not possible under local conditions
(strong agreement)
3 Endoscopic therapy of bleeding gastric varices is
based on obturation with tissue adhesives (strong
agreement)
15 In GI bleeding in patients with cirrhosis, there is no indication
for administration of fresh-frozen plasma before EGD (strong
agreement)
7 In massive or persistent lower GI bleeding, the small
intestine should be examined as soon as possible
when CT angiography and colonoscopy fail to locate
the source of bleeding (strong agreement)
4 Vasoactive treatment should be continued for 3 to 5
days after endoscopic therapy of esophageal/gastric
varices rupture (strong agreement)
16 In GI bleeding in patients with cirrhosis, there is no indication
for the administration of factor VIIa (strong agreement)
Area 5: Prevention of upper GI bleeding in intensive care
5 In adults, after endoscopic hemostasis of bleeding
related to portal hypertension, the placement of a
TIPS within 72 h should be considered in high-risk
patients (strong agreement)
17 In GI bleeding in patients with cirrhosis, platelet transfusion
should probably be considered when bleeding is uncontrolled
and platelet count is <30,000/mm3(strong agreement)
1 Patients with a history of peptic ulcer admitted to
intensive care should probably be considered at risk
of GI bleeding (strong agreement)
6 Balloon tamponade should be considered after
endoscopy failure pending radical treatment of
portal hypertension. In child, its use should probably
be envisaged if emergency EGD is not possible (strong
agreement)
18 In adults, in esophageal/gastric bleeding, beta-blocker treatment
should be started when vasoactive treatment is discontinued
(strong agreement)
2 Early enteral feeding is effective in preventing “stress
ulcer” bleeding (strong agreement)
7 Antibiotic prophylaxis with third-generation
cephalosporin or with fluoroquinolone for 5 to 7 days
should be given to any cirrhotic patient with GI bleeding
(strong agreement)
19 After ligation of esophageal varices, nasogastric intubation
should probably be avoided (expert opinion, strong agreement)
3 Patients requiring mechanical ventilation for more
than 48 h and for whom enteral feeding is not
possible should be considered to be at risk of “stress
ulcer” bleeding (strong agreement)
8 Lactulose treatment to prevent hepatic encephalopathy
should probably not be initiated during GI bleeding in
a cirrhotic patient (expert opinion, strong agreement)
Area 4: Management of presumed lower GI bleeding 4 Patients admitted to intensive care with kidney failure
and/or coagulopathy and/or receiving antiplatelet
therapy should be considered to be at risk of “stress
ulcer” bleeding (strong agreement)
9 In adults, PPI therapy should not be initiated or
continued when EGD has confirmed a diagnosis
of ruptured esophageal/gastric varices (strong
agreement)
1 In adults with massive hematochezia, demonstration of active
bleeding by abdominal CT angiography or arteriography justifies
embolization as first-line therapy (strong agreement)
5 Routine drug prophylaxis of “stress ulcer” should not
be used in intensive care patients with enteral feeding
(strong agreement)
10 In children, PPI therapy should probably be initiated
or continued in case of esophageal/gastric varices
rupture (weak agreement)
2 In massive hematochezia, and in the absence of detectable
bleeding on CT angiography or arteriography a prepared
colonoscopy should be performed within 24 h (strong agreement)
6 Ulcer prophylaxis medication should probably be
given routinely in intensive care patients with a history
of peptic ulcer (even if enterally fed) (weak agreement)
11 One objective of hemodynamic treatment during
esophageal/gastric varices rupture should be to restore
a satisfactory mean blood pressure to preserve tissue
perfusion (strong agreement)
3 In massive and persistent hematochezia, and in the
absence of detectable bleeding on abdominal CT angiography
or arteriography, a prepared colonoscopy should probably be
done within 12 h with the objective of performing endoscopic
hemostasis (strong agreement)
7 Ulcer prophylaxis medication should probably be given
routinely to intensive care patients receiving
antiplatelet therapy (even if enterally fed) (weak
agreement)
12 In adults, during esophageal/gastric varices rupture,
early hemodynamic treatment should probably maintain
mean blood pressure at approximately 65 mmHg in
most patients (strong agreement)
4 In adults with massive hematochezia, rectosigmoidoscopy
should probably be done if full colonoscopy cannot be
performed within 24 h (strong agreement)
8 In the absence of enteral feeding, ulcer prophylaxis





















Table 1 Recommendations for management by the intensivist of gastrointestinal bleeding (Continued)
9 In the absence of enteral feeding, ulcer prophylaxis
medication should probably be given to patients with
coagulopathy (weak agreement)
13 A large bore nasogastric tube for aspiration should
probably be replaced by a small-calibre enteral
tube as soon as possible (expert opinion, strong
agreement)
10 In children, a pediatric risk of mortality score (PRISM) >
10 associated with respiratory failure or coagulopathy
or both probably calls for ulcer prophylaxis (strong
agreement)
14 Antacids should not be used to prevent “stress ulcer”
bleeding (strong agreement)
11 Screening for Helicobacter pylori should not be routine
in intensive care patients (strong agreement)
15 H2 receptor antagonists and PPIs are probably
comparable but of low efficacy in preventing
“stress ulcer” bleeding (weak agreement)
12 A nasogastric tube should probably be removed once
it is no longer used (expert opinion, strong agreement)
16 H2 receptor antagonists and PPIs are probably
comparable regarding the risk ventilator associated
pneumonia during mechanical ventilation (strong
agreement)




















Table 2 Rockall score
Score 0 1 2 3
Age (yr) <60 60-70 >80
Shock No shock Pulse >100
SBP >100 mmHg
Comorbidity No No Ischemic heart disease Renal failure
Cardiac failure Liver failure
Major comorbidity Disseminated malignancy
Diagnosis Mallory Weiss tear or All other diagnoses Gastrointestinal malignancy
No lesion
Evidence of bleeding None or Blood
Dark spot Visible or spurting vessel
Adherent clot
A total score less than 3 carries good prognosis and total score more than 8 carries high risk of mortality.
SBP, systolic blood vessel.
From Rockall TA, Gut 1996.
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proposed recommendations were presented and discussed
one by one. The aim was not necessarily to reach a single
and convergent opinion for all proposals, but rather to
highlight points of agreement, and points of disagreement
or indecision. Each recommendation was then scored by
each of the experts on a scale of 1 (complete disagreement)
to 9 (complete agreement). The collective scoring was
established using the RAND/UCLA appropriateness
method [9]: after elimination of the extreme values (out-
liers), the median and confidence interval of the individualTable 3 Glasgow-Blatchford score
Admission risk marker Score
Blood urea (mmol/l) ≥6.5 et < 8 2
≥8 et < 10 3
≥10 et < 25 4
≥25 6
Hemoglobin (g/L) for men ≥12 et < 13 1
≥10 et < 12 3
<10 6
Hemoglobin (g/L) for women ≥10 et < 12 1
<10 6
Systolic blood pressure (mmHg) ≥100 et < 109 1
≥90 et < 100 2
<90 3





A total score more than 8 carries high risk justifying ICU admission.
From Blatchford O, Lancet 2000.scores were calculated. The median defined agreement be-
tween the experts when it was between 1 and 3, disagree-
ment between 7 and 9 and indecision between 4 and 6.
The agreement, disagreement, or indecision was “strong” if
the confidence interval was within one of three ranges:
(1–3), (4–6), or (7–9) and “weak” if the confidence interval
straddled two ranges. In the absence of strong agreement,
the recommendations were reformulated and again scored
with a view to achieving a better consensus. Three rounds
of scoring were therefore performed.
Area 1: Management of GI bleeding before endoscopic
diagnosis
1. Nasogastric intubation may help confirm, but cannot
discount, suspected upper GI bleeding (strong
agreement).
Upper GI bleeding should always be diagnosed by
esophagogastroduodenoscopy (EGD) [2,10]. Pending
endoscopy, insertion of a nasogastric tube can guide the
diagnostic approach, notably in a setting of acute an-
aemia or hemorrhagic shock. Three recently compiled
retrospective analyses assessed the capacity of nasogas-
tric aspiration to differentiate an upper from a lower
source of GI bleeding [11]. Apart from one study, the
design of which probably generated a high proportion
of false positives, insufficient negative predictive values
were reported (61%; 95% CI 53–68 and 64%; 95% CI
43–80), albeit associated with very satisfactory positive
predictive values (81%; 95% CI 69–90 and 93%; 95%
CI 81–98) [11].
2. Suspected rupture of esophageal/gastric varices
probably does not contraindicate nasogastric
intubation (strong agreement).
Table 4 Forrest classification
Class Risk of rebleeding
Clean base III low
Hematin covered flat spot IIc low
Adherent clot IIb high
Visible vessel IIa high
Oozing hemorrhage Ib high
Spurting hemorrhage Ia high
From Laine L, New Engl J Med 1994.
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insertion when rupture of esophageal varices is suspected
is unknown. In a population admitted to hospital because
of rupture of esophageal varices in approximately 35% of
cases, gastric lavage after nasogastric tube placement was
compared with intravenous erythromycin for GI endos-
copy preparation [12]. There was no between-group dif-
ference in rebleeding frequency or in the number of
transfused blood units [12].
3. To ensure emptying of the stomach content before
EGD, intravenous erythromycin should be administered
at a dose of 250 mg (5 mg/kg in children), in the
absence of contraindications (strong agreement).
4. If a nasogastric tube has been inserted, gastric lavage
to empty the stomach is an alternative to
administration of erythromycin (weak agreement).
In a recent meta-analysis, the use of a prokinetic agent
(erythromycin or metoclopramide) was associated with
reduced need for a repeat EGD (odds ratio [OR] 0.55;
95% CI 0.32-0.94) [13].In contrast, there was no im-
provement in the length of hospital stay, the need for
surgery, or the number of transfused blood units [13].
Erythromycin is useful in bleeding ulcer and in bleeding
associated with portal hypertension [14,15]. Last, a re-
cent study found no difference between erythromycin,
gastric lavage, and the two combined in term of condi-
tions for endoscopy [12]. Nasogastric intubation was,
however, often poorly tolerated and caused pain [12].
5. In adults, the Rockall score and the Glasgow-
Blatchford bleeding score can probably help to
identify patients at high risk of morbidity and
mortality and to refer them to an intensive care unit
(strong agreement).
The Rockall score and the Glasgow-Blatchford bleeding
score, which have been validated in many studies [16,17],
were developed for early identification of high-risk
patients needing intensive care and of low-risk patients
who can be discharged early. The Rockall score (Table 2)
comprises clinical, biochemical, and endoscopic data and
is correlated with the risk of rebleeding [18]. The
Glasgow-Blatchford bleeding score (Table 3) includes
clinical and biochemical data, but not EGD, and is useful
to predict the need for intervention (hospitalization,
transfusion, surgery) or death [19].
6. EGD should be done in the 24 h following the
admission of a patient with suspected upper GI
bleeding (strong agreement).
7. EGD probably should be done in the 12 h
following the admission of the patient withsuspected esophageal/gastric variceal bleeding
(strong agreement).
8. EGD probably should be done as soon as possible,
and once the patient is resuscitated, when active
upper GI bleeding is suspected (strong agreement).
EGD within 24 h after admission of a patient with
suspected upper GI bleeding reduces transfusion require-
ment, second-look endoscopy, and emergency surgery
[2,10,20]. However, the influence of this 24-h interval on
mortality remains controversial [2,10,20]. Earlier EGD
(within 6 to 12 h) is subject to debate. A meta-analysis of
three randomized trials [2] showed no benefit of early
endoscopy in terms of mortality, rebleeding, or need for
surgery. In high-risk patients, however, early endoscopy
may prove valuable. One study showed that early endos-
copy in patients with blood in gastric aspirates was asso-
ciated with reduced transfusion requirement and reduced
hospital stay [21]. Another study identified independent
predictors of benefits of early EGD that included fresh
blood in gastric aspirates, hemodynamic instability, and
hemoglobin <8 g/dL [22]. A recent study showed that
when the Glasgow-Blatchford score was ≥12, the mortality
of patients in whom endoscopy was performed within
the first 13 h was lower than in those who underwent
endoscopy after 13 h [23]. Lastly, when esophageal/
gastric variceal bleeding is suspected, EGD in the first
12 h is usually recommended [5,24].
9. In massive hematochezia and/or with hemodynamic
consequences, an EGD should be performed as soon
as possible (strong agreement).
Approximately 10% of cases of massive hematochezia
are related to upper GI bleeding, thus justifying EGD be-
fore colonoscopy [25]. When the upper GI endoscopic
findings are normal, the question sometimes arises
whether to repeat EGD before colonoscopy. EGD need
not be repeated if no blood is found in the upper GI tract
on a first examination performed in good conditions [26].
10. In adults, in massive hematochezia and/or with
hemodynamic consequences, an abdominal CT
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if EGD is not rapidly available and/or if an
aortoenteric fistula is suspected (strong agreement).
Several studies have shown the great value of abdom-
inal CT angiography in topographic diagnosis of upper
or lower GI bleeding [27-29]. Improved CT angiography
techniques also can be used for etiological diagnosis and
to guide treatment [29,30]. CT angiography enables
timely recognition of the rare aortoenteric fistulas [31].
11. In children, in massive hematochezia and/or with
hemodynamic consequences, and when GI
endoscopic findings are normal, an emergency
scintigraphy to search for a Meckel’s diverticulum
should be used and/or a surgical exploration
(McBurney’s incision or coelioscopy)
(strong agreement).
In children, massive hematochezia is infrequent and
mostly caused by variceal rupture in a setting of portal
hypertension or Meckel’s diverticulum. More rarely, vas-
cular malformations of the colon or small intestine are
observed [32]. If the GI endoscopic findings are normal,
thus discounting rupture of varices, scintigraphy or even
surgical exploration should be performed to search for a
Meckel’s diverticulum [33].
12. Vasoactive treatment (terlipressin or somatostatin
or a somatostatin derivative) should be
administered as soon as possible when portal
hypertension is the suspected cause of GI bleeding
(strong agreement).
Vasoactive medication will stop bleeding in 75% to
80% of cases [24]. A literature analysis suggests that
once portal hypertension is clinically suspected, includ-
ing at the prehospital management phase, vasoactive
medication improves the quality of patient transport
and then of the EGD [5,34]. Two drug classes are avail-
able: vasopressin derivatives (in particular terlipressin)
and synthetic derivatives of somatostatin (octreotide,
vapreotide). Comparison of somatostatin with terlipres-
sin showed similar first bleeding, rebleeding, and
mortality rates [35]. Combined with endoscopic ther-
apy, octreotide significantly reduces rebleeding in com-
parison with placebo [36-38]. Lastly, octreotide was
better than vasopressin [39] and equivalent to terlipres-
sin [40].
13. In a patient already treated with noradrenaline,
specific vasoactive treatment of the splanchnic area
(terlipressin, somatostatin, somatostatin derivative)
should probably be administered when portalhypertension is the suspected cause of GI bleeding
(expert opinion, weak agreement).
14. Specific vasoactive treatment of the splanchnic area
(terlipressin, somatostatin, somatostatin derivative)
should probably not be administered when portal
hypertension is not the suspected cause of
GI bleeding (weak agreement).
A 1997 meta-analysis showed that somatostatin treat-
ment had benefits in a setting of upper GI bleeding un-
related to portal hypertension [41]. The comparison was,
however, made with an H2 receptor antagonist and a
placebo [41] and no study has examined this question
since the advent of PPIs.
15. In GI bleeding potentially caused by ulcers, PPI
treatment should be started without waiting for
endoscopic diagnosis (weak agreement).
16. In GI bleeding potentially caused by ulcers,
high-dose PPI treatment should probably be
administered (weak agreement).
A recent meta-analysis showed that PPIs at “standard”
doses (compared with no treatment, placebo, or an H2
receptor antagonist) administered beforehand facilitated
EGD by reducing the proportion of patients with stig-
mata of recent hemorrhage or active bleeding and by
reducing requirement for endoscopic therapy [42]. One
study showed that before endoscopic therapy, the ad-
ministration “high” PPI doses, compared with placebo,
reduced transfusion requirement, rebleeding, and hos-
pital stay [43]. This question has not been examined by
comparing “high” and “standard” doses.Area 2: Treatment of upper GI bleeding unrelated to
portal hypertension
1. In the presence of stigmata associated with a low risk
of rebleeding (Forrest type IIc and III), endoscopic
hemostasis should not be used (strong agreement).
The natural history of ulcer disease shows a rebleeding
rate of approximately 5% only in the case of Forrest type
IIc or III (Table 4) [44].
2. In the presence of stigmata associated with a low
risk of rebleeding (Forrest type IIc and III),
PPI treatment at “standard” doses should be
continued (strong agreement).
PPIs at “standard” doses have proven effective in pep-
tic ulcer and recent French recommendations reiterate
that there is no difference between the five available PPIs
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rabeprazole) [45].
3. In the presence of stigmata associated with a high
risk of rebleeding (Forrest type Ia, Ib, IIa), endoscopic
hemostasis should be performed (strong agreement).
A meta-analysis confirmed that endoscopic therapy
reduces rebleeding risk (Forrest type Ia, Ib, IIa) compared
with intravenous PPIs alone (OR 0.56; 95% CI 0.34-0.92)
[46]. Another meta-analysis confirmed the value of endo-
scopic therapy in this high-risk population by showing
that PPI treatment only reduces mortality if endoscopic
therapy has been done [47]. Lastly, the literature recom-
mends combined endoscopic therapy (epinephrine + clips
or thermal devices) and not epinephrine alone [48].
4. In the presence of an adherent clot (Forrest type IIb),
endoscopic hemostasis is possible when the clot is
small (strong agreement).
The usual approach to an adherent clot is to seek to
dislodge it by irrigation. When the clot is resistant to
washing, reported rebleeding rates range from 0% [49]
to 35% [50]. Two meta-analyses showed no advantage of
endoscopic therapy over medical therapy [48,51]. In con-
trast, no data suggestan excess risk related to endoscopic
therapy and a systematic review showed a low incidence
of complications [52].
5. In the presence of stigmata associated with a high
risk of rebleeding (Forrest type Ia, Ib, IIa, IIb), PPI
treatment should be continued at “high” doses for
72 h (strong agreement).
PPIs have been proposed to prevent early rebleeding
after spontaneous or endoscopic hemostasis and several
studies suggest they are beneficial at “high” doses (accord-
ing to the regimen initially proposed with intravenous
omeprazole: 80 mg in 30 min, then 8 mg/h for 72 h). The
first quality study showed that PPIs at “high” doses,
compared with placebo, significantly reduced the risk of
recurrent bleeding (hazard ratio 3.9; 95% CI 1.7-9), but
no difference in need for surgery or death [53]. A
meta-analysis showed that PPI treatment with or without
endoscopic therapy, compared with placebo or an H2
receptor antagonist, reduced the risk of rebleeding
(OR 0.45; 95% CI 0.36-0.57) and the need for surgery
(OR 0.56; 95% CI 0.45-0.7), but not mortality [54].
Complementary analyses showed that in patients with
active bleeding or visible blood vessels who were receiv-
ing hemostatic treatment, a high intravenous dose of
PPI reduced rebleeding, surgery, and also mortality
(OR 0.57; 95% CI 0.34-0.96) [54]. Two meta-analysesshowed no effect on mortality of lower doses of PPI
[48,54]. Lastly, a randomized study [55] of esomeprazole
(80 mg then 8 mg/h for 72 h) compared with placebo in
patients with peptic ulcer bleeding (Forrest type Ia to IIb)
who received endoscopic therapy showed a significant re-
duction in recurrent bleeding at 72 h (5.9% vs. 10.3%) and
for up to 30 days [55]. In contrast, there was no advantage
to the use of esomeprazole in terms of surgery or all-cause
mortality rate [55]. A recent meta-analysis (7 randomized
studies, 1,157 patients) comparing high-dose PPI (80 mg
of omeprazole or pantoprazole then 8 mg/h for 72 h) with
non-high-dose PPI found no difference in the rates of
rebleeding, surgical intervention, or mortality [56]. The
study did, however, have several limitations: the analysis
was not intention to treat, studies of insufficient power
were included, and quite high doses of PPI were in fact
administered in the non-high-dose groups. Lastly, cost-
effectiveness analyses showed that high-dose PPIs were
beneficial after successful endoscopic hemostasis [17,57].
6. Second-look EGD should not be done routinely
(strong agreement).
7. Second-look EGD probably should be done when a
high-risk stigmata has been observed (weak
agreement).
Second-look EGD is scheduled for 16 to 24 h after the
initial endoscopy. A 2010 meta-analysis evaluated the
value of second-look endoscopy with thermal coagula-
tion or injection of adrenaline [58]. Thermal coagulation
reduced recurrent bleeding (4.2% vs. 15.7%, relative risk
0.29; 95% CI 0.11-0.73) but had no effect on need for
surgery or mortality. Second-look endoscopy with injec-
tion of adrenaline was not associated with any benefit. A
meta-analysis done for the 2010 international consensus
conference [2] suggested that second-look endoscopy
reduces the risk of rebleeding (OR 0.59; 95% CI 0.38-
0.91) and surgery (OR 0.43; 95% CI 0.19-0.96), but not
mortality. Second-look endoscopy reduced rebleeding by
33% (p=0.03) in a study in which 47% of the patients
were in a state of shock [59]. Saeed et al. showed in
patients at high hemorrhagic risk according to the Forr-
est classification, a reduction in rebleeding from 24% to
0% (p< 0.05) [60]. Two meta-analyses showed a signifi-
cant reduction in hemorrhagic risk (respectively, relative
risk 0.29 and OR 0.59) in at-risk patients [46,61]. The
cost-effectiveness ratio of a strategy involving routine
second-look EGD has not yet been assessed.
8. Patients with ulcer bleeding should not be treated
with H2 receptor antagonists (strong agreement).
A 1985 meta-analysis of 27 studies of H2 receptor
antagonists suggested that they marginally reduced
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gastric ulcer [62]. This was confirmed by a more recent
meta-analysis [63]. Following the June 16, 2011 meeting
of the French Transparency Commission, it was con-
cluded that H2 receptor antagonists are of little thera-
peutic benefit in peptic ulcer-related bleeding.
9. In adults, in case of Forrest type Ia and Ib,
first-intention selective arterial embolization by
interventional radiology should probably be used
following failure of endoscopic therapy
(weak agreement).
10. In adults, in case of Forrest type Ia and Ib and
catastrophic bleeding, first-intention surgical
hemostasis should probably be used following
failure of endoscopic therapy if local
conditions do not allow arterial embolization
(strong agreement).
If endoscopic therapy fails, percutaneous transcatheter
arterial embolization is an alternative to surgery, notably
in patients at a high surgical risk. A recently published
analysis of 35 studies and 927 patients showed that the
technical and clinical success rates of embolization ran-
ged from 52% to 100% and 44% to 100%, respectively
[64]. Rebleeding was observed in 0 to 55% of cases de-
pending on the study. Successful embolization improved
survival 13.3-fold [64]. Retrospective comparisons be-
tween surgery and embolization showed equivalent clin-
ical success and mortality, although embolization was
applied to an older population with a higher prevalence
of comorbidities [64].
11. Biopsy screening for Helicobacter pylori infection
can be performed during the first EGD for GI
bleeding without worsening the bleeding
(strong agreement).
No study has evaluated the hemorrhagic risk linked to
gastric biopsy during upper GI bleeding. In a prospect-
ive, case–control study, gastric biopsies were performed
to screen for Helicobacter pylori in 324 patients with GI
bleeding and 164 patients with uncomplicated ulcer [65].
The hemorrhagic risk in the group admitted for GI
bleeding was not increased [65]. However, the sensitivity
of the rapid urease test was significantly lower in this
group (false-negative 16.7% vs. 5.6%) [65].
12. There is probably no advantage to emergency
treatment of Helicobacter pylori infection in the
case of GI ulcer bleeding (strong agreement).
A meta-analysis clearly established that eradication
therapy of Helicobacter pylori infection compared with“conventional” (OR 0.17; 95% CI 0.1-0.32) or “pro-
longed” (OR 0.25; 95% CI 0.08-0.76) antisecretory ther-
apy, reduced the long-term (1 year or more) risk of
recurrent bleeding [66]. In contrast, no study has shown
that eradication therapy is useful in early rebleeding.
13. Aspirin antiplatelet therapy should probably be
maintained in the case of GI ulcer bleeding until
consultation with specialists (weak agreement).
14. In dual antiplatelet therapy, clopidogrel should
probably be stopped in the case of ulcer
bleeding until consultation with specialists
(strong agreement).
A meta-analysis showed that discontinuing or not ad-
hering to aspirin given preventively was associated with
a threefold higher risk of major adverse cardiac events
[67]. Stoppage of antiplatelet treatment in a hemorrhagic
setting probably yields no immediate benefit because an
antithrombotic effect persists for 7 to 10 days [68]. A
randomized study in patients with aspirin-induced pep-
tic ulcer suggested that early reintroduction of aspirin or
clopidogrel was possible [69]. Another randomized study
in 156 patients with aspirin-induced ulcer bleeding who
received endoscopic therapy and PPI treatment showed
that immediate reintroduction of aspirin was associated
with a twofold higher risk, albeit not statistically signifi-
cant, of rebleeding [70]. Conversely, discontinuation of
aspirin was associated with a significant increase in mor-
tality at 8 weeks [70].Area 3: Treatment of upper GI bleeding related to portal
hypertension
1. Endoscopic therapy of bleeding esophageal/gastric
varices should be done during initial EGD (strong
agreement).
2. Endoscopic therapy of bleeding esophageal varices is
based on band ligation. Sclerotherapy is an
alternative in the very young child (strong agreement).
3. Endoscopic therapy of bleeding gastric varices is
based on obturation with tissue adhesives (strong
agreement).
EGD is the key examination in management of GI
bleeding in cirrhotic patients [5]. No study indicates the
best timing, but international recommendations advise
as soon as possible (within 12 h) in a resuscitated patient
[5]. It is now clear that the treatment of choice in
esophageal varices is band ligation, which controls active
bleeding and reduces the rebleeding rate with fewer ad-
verse effects than sclerosis [71]. Obturation using cyano-
acrylate glue, which is technically more difficult than
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varices [72].
4. Vasoactive treatment (terlipressin or somatostatin or
somatostatin derivative) should be continued for 3 to
5 days after endoscopic therapy of esophageal/gastric
varices rupture (strong agreement).
Combined (vasoactive and endoscopic) treatment is
more effective than endoscopic therapy in controlling
bleeding from esophageal/gastric varices. No clear re-
duction in mortality by a combined treatment has been
demonstrated. The length of vasoactive treatment has
not been evaluated in dedicated trials. Sung et al.
observed significantly less recurrent bleeding at 48 h in
patients treated by ligation and octreotide compared
with in those treated by ligation alone [37]. The combin-
ation of sclerotherapy and somatostatin for 5 days was
more effective than sclerotherapy alone [73]. Besson
et al. combined sclerotherapy and octreotide (25 μg/h)
for 5 days and observed increased survival without
rebleeding 5 days after sclerotherapy [36]. In another
study, survival without rebleeding at 5 days was greater
in the group of patients treated with endoscopy and
vapreotide than in the group treated with endoscopy and
placebo [74].
5. In adults, after endoscopic hemostasis of bleeding
related to portal hypertension, the placement of a
transjugular intrahepatic portosystemic shunt (TIPS)
within 72 h should be considered in high-risk
patients (Child-Pugh class B with active bleeding and
Child-Pugh class C) (strong agreement).
Two studies showed that early placement of TIPS
reduces the risk of failure to control bleeding and
rebleeding in patients at high risk of recurrence [75,76].
In the more recent study, high-risk patients were defined
as Child-Pugh class B patients with persistent bleeding
at the time of EGD or Child-Pugh class C patients [76].
Improvement of survival following TIPS placement also
was demonstrated compared with the control group
(13% vs. 39%) [76].
6. Esophageal/gastric balloon tamponade should be
considered after failure of endoscopic therapy
pending radical treatment of portal hypertension.
In children, its use should probably be envisaged if
emergency EGD is not possible (strong agreement).
The Sengstaken-Blakemore tube (with two balloons
for esophageal varices) and the Linton-Nachlas tube
(single balloon for gastric cardia varices or fundal vari-
ces) were tested in a 1988 old studies for tamponade ofbleeding varices. The success rate was 40% to 90%, but
there were numerous complications (inhalation lung dis-
ease, esophageal ulceration, and rupture) and rebleed-
ing occurred in approximately one of two cases [77].
7. Antibiotic prophylaxis with third-generation
cephalosporin or with fluoroquinolone for 5 to 7
days should be given to any cirrhotic patient with GI
bleeding (strong agreement).
A bacterial infection is noted in approximately 40% of
cirrhotic patients in the 7 days following their admission
for upper GI bleeding [78]. These infections are inde-
pendently associated with the risk of rebleeding and with
mortality [79]. A meta-analysis has clearly established
that prophylactic antibiotic therapy significantly reduces
infection (by 32%; 95% CI 22–42) and death (by 9%; 95%
CI 2.9-15.3) [80]. The oral administration of a quinolone
is recommended in most patients [5,81]. Intravenous
quinolone is possible if the oral route is not available. A
recent study in a population of patients with advanced
cirrhosis (Child-Pugh class B or C) showed that intra-
venous ceftriaxone was associated with a lower infection
rate than oral norfloxacin [82]. International recommen-
dations state that intravenous ceftriaxone should be con-
sidered as prophylactic antibiotic therapy in this
population [5].
8. Lactulose treatment to prevent hepatic
encephalopathy should probably not be
initiated during GI bleeding in a cirrhotic patient
(expert opinion, strong agreement).
9. In adults, PPI therapy should not be initiated or
continued when EGD has confirmed a diagnosis
of ruptured esophageal/gastric varices
(strong agreement).
10. In children, PPI therapy should probably be
initiated or continued in case of esophageal/gastric
varices rupture (weak agreement).
Esophageal ulceration is a possible complication of
variceal ligation. In a randomized, controlled trial, PPI
therapy reduced the size, but not the number, of postli-
gation ulcers [83]. Several retrospective studies suggest
that PPIs may increase the risk of bacterial infection in
this population [84]. In children, however, gastritis is fre-
quently associated with portal hypertension [85].
11. One objective of hemodynamic treatment during
esophageal/gastric varices rupture should be to
restore a satisfactory mean blood pressure to
preserve tissue perfusion (strong agreement).
12. In adults, during esophageal/gastric varices
rupture, early hemodynamic treatment should
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approximately 65 mmHg in most patients
(strong agreement).
In cirrhosis, portal pressure seems to be related linearly
to plasma volume and may affect the severity of bleeding
[86]. The target mean blood pressure is not well known in
this population. On the basis of extrapolation of recom-
mendations established for hemorrhagic shock in trauma
patients [87], but also for septic shock [88], a mean blood
pressure of approximately 65 mmHg can be proposed.
13. Blood transfusion in most patients should probably
target a hemoglobin concentration of 7 to 8 g/dL
(strong agreement).
The target hemoglobin concentration in esophageal/
gastric varices rupture is not clearly defined. In trauma
patients with hemorrhagic shock, a target hemoglobin
concentration of 7 to 9 g/dL has been proposed [87].
Restricted blood transfusion (hemoglobin concentration
7 to 8 g/dL) also is recommended in the specific con-
text of GI bleeding related to portal hypertension [5].
14. In GI bleeding in patients with cirrhosis, there is
probably no indication for administration of fresh-
frozen plasma with the objective to correct a
coagulopathy (strong agreement).
15. In GI bleeding in patients with cirrhosis, there is no
indication for administration of fresh-frozen plasma
before EGD (strong agreement).
In hemorrhagic shock due to trauma, early treatment
with fresh-frozen plasma is recommended when bleed-
ing is massive [87] but is much debated in cirrhotic
patients [5]. An association between this type of trans-
fusion and the risk of excessive plasma volume in-
crease and worsening of portal hypertension has been
suggested [10]. Lastly, prothrombin time and inter-
national normalized ratio are not good indicators for
coagulability in patients with cirrhosis and attempts to
correct them are therefore not recommended [5].
16. In GI bleeding in patients with cirrhosis, there is no
indication for the administration of factor VIIa
(strong agreement).
A recent randomized trial in patients with cirrhosis
and variceal bleeding found no difference between factor
VIIa and placebo in terms of control of bleeding or
survival [89].
17. In GI bleeding in patients with cirrhosis, platelet
transfusion should probably be considered whenbleeding is uncontrolled and platelet count is
<30,000/mm3(strong agreement).
Platelet transfusion in severe bleeding is usually recom-
mended when platelet count is <50,000/mm3 [87,90]. No
study has examined this question in the particular setting
of GI bleeding in the cirrhotic patient. The risk of wor-
sening portal hypertension has been raised [10].
Thrombocytopenia is common in the cirrhotic patient
and is a poor indicator of hemorrhagic risk [5]. On the
basis of these arguments, a transfusion is usually recom-
mended for a platelet count <30,000/mm3 but should not
delay endoscopy [5,10].
18. In adults, in esophageal/gastric bleeding,
beta-blocker treatment should be started
when vasoactive treatment is discontinued
(strong agreement).
Secondary prophylaxis of bleeding from esophageal/
gastric varices is based on the combination of noncar-
dioselective beta-blockers and repeated ligation [5]. Early
introduction of beta-blockers seems to avoid a rebound
effect of portal hypertension favoring rebleeding. A re-
cent meta-analysis of 23 studies showed that combined
treatment (beta-blocker and ligation) significantly
reduced rebleeding in comparison with endoscopic ther-
apy alone (OR 0.68; 95% CI 0.52-0.89) or pharmaco-
logical treatment alone (OR 0.71; 95% CI 0.59-0.86) [91].
The median interval to introduction of beta-blockers
was 3 (range 1–7) days [91].
19. After ligation of esophageal varices, nasogastric
intubation should probably be avoided
(expert opinion, strong agreement).
Area 4: Management of presumed lower GI bleeding
1. In adults with massive hematochezia, demonstration
of active bleeding by abdominal CT angiography or
arteriography justifies embolization as first-line
therapy (strong agreement).
After angiographic localization of bleeding, the
hemostatic efficacy of embolization is approximately
90%. One study showed, however, that embolization was
associated with an approximately 10% risk of recurrent
bleeding and more rarely a risk of colonic ischemia [92].
In approximately 5% of cases, embolization was technic-
ally impossible [92].
2. In massive hematochezia, and in the absence of
detectable bleeding on abdominal CT angiography or
arteriography (or scintigraphy in children), a
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24 h (strong agreement).
3. In massive and persistent hematochezia, and in the
absence of detectable bleeding on abdominal CT
angiography or arteriography, a prepared
colonoscopy should probably be done within 12 h
with the objective of performing endoscopic
hemostasis (strong agreement).
Colonoscopy identifies the cause of hematochezia in
approximately 75% of cases [93]. Colonoscopy after
preparation is therefore recommended within 24 h
[25,94]. If hematochezia persists, colonoscopy within a
shorter timeframe (12 h) should be considered, notably
with a view to hemostatic treatment [95-100]. Initial
endoscopic hemostasis is successful in nearly 95% of
cases [93,94,101,102]. In contrast, the results in terms of
definitive hemostasis vary from one study to another. In
all these studies the risk of complications of colonic
endoscopic hemostasis was low or zero.
4. In adults with massive hematochezia,
rectosigmoidoscopy probably should be done if full
colonoscopy cannot be performed within 24 h
(strong agreement).
In the 80% of cases when bleeding ceases spontan-
eously, a prepared colonoscopy should be performed as
soon as possible [103]. Early colonoscopy increases the
chances of identifying the cause of bleeding and of pro-
posing endoscopic hemostasis [93,95,96,98,99]. In con-
trast, the prognostic value of early colonoscopy seems
more questionable [96]. Rectosigmoidoscopy, often per-
formed in imperfect conditions in terms of preparation
and safety, rarely dispenses with the need for full colon-
oscopy [25,94].
5. When lower GI bleeding is massive, surgical
hemostasis should be proposed in case of arterial
embolization or colonoscopy failure or rebleeding
(strong agreement).
6. When lower GI bleeding is catastrophic, surgical
hemostasis should be performed if arterial
embolization is not possible under local conditions
(strong agreement).
The indications for surgical hemostasis have been con-
siderably reduced because of advances in embolization
and in endoscopic therapy and are limited to failure of
embolization or of colonoscopy or of both [25,94]. Such
situations essentially concern diverticular bleeding. If
there is an indication for surgery, an attempt should be
made to determine the site of bleedingin order to adapt
the surgical procedure. When the site of bleeding isknown with certainty, partial colectomy should be per-
formed. In diffuse colonic diverticulosis when the site of
bleeding is unidentified, subtotal colectomy should be
preferred.
7. In massive or persistent lower GI bleeding, the small
intestine should be examined as soon as possible
when CT angiography and colonoscopy fail to
locate the source of bleeding (strong agreement).
When the cause of bleeding is unknown, small intes-
tine involvement should be considered whenever ter-
minal ileoscopy (which should be routine during
colonoscopic examination of lower GI bleeding) reveals
blood or mucosal anomalies [104]. Etiological diagnosis
of small intestine bleeding often is difficult [105]. Endo-
scopic techniques (capsule endoscopy, enteroscopy)
usually enable diagnosis [105]. The data on endoscopic
hemostasis of bleeding in the colon can be transposed
to small intestine lesions accessible to endoscopy, albeit
with a probably higher risk of complications.
Area 5: Prevention of upper GI bleeding in intensive care
1. Patients with a history of peptic ulcer admitted to
intensive care probably should be considered at risk
of GI bleeding (strong agreement).
A 1983 retrospective analysis of patients admitted to
medical-surgical intensive care unit defined a risk score
for upper GI bleeding in intensive care as the sum of
coefficients associated to 24 risk factors [106]. A history
of ulcers was associated with the most determinant coef-
ficient [106], a result confirmed by another study [107].
It also should be emphasized that patients with a peptic
ulcer within the previous month or year often are
excluded from studies that analyze upper GI bleeding in
intensive care [108,109].
2. Early enteral feeding is effective in preventing
“stress ulcer” bleeding (strong agreement).
3. Patients requiring mechanical ventilation
for more than 48 h and for whom enteral
feeding is not possible should be considered
to be at risk of “stress ulcer” bleeding
(strong agreement).
4. Patients admitted to intensive care with kidney
failure and/or coagulopathy and/or receiving
antiplatelet therapy should be considered
to be at risk of “stress ulcer” bleeding
(strong agreement).
5. Routine drug prophylaxis of “stress ulcer” should not
be used in intensive care patients with enteral feeding
(strong agreement).
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given routinely in intensive care patients with a
history of peptic ulcer (even if enterally fed)
(weak agreement).
7. Ulcer prophylaxis medication probably should be
given routinely to intensive care patients receiving
antiplatelet therapy (even if enterally fed)
(weak agreement).
8. In the absence of enteral feeding, ulcer prophylaxis
medication should probably be given to ventilated
patients (weak agreement).
9. In the absence of enteral feeding, ulcer prophylaxis
medication should probably be given to patients with
coagulopathy (weak agreement).
Several criteria, including mechanical ventilation
[109-111], coagulopathy [109,110], kidney failure [111],
and lack of enteral feeding [111], have been identified as
risk factors, sometimes independent, for upper GI
bleeding in intensive care. In 174 patients, mechanical
ventilation for more than 5 days and coagulopathy
(defined by platelet count <50 000/mm3, effective antic-
oagulation or lengthening of the partial thromboplastin
time) were the risk factors most strongly associated with
upper GI bleeding [110]. In a vast prospective and mul-
ticenter analysis in 2,252 patients, Cook et al. identified
mechanical ventilation of more than 48 h (OR 15.6) and
coagulopathy (OR 4.3) as the only two risk factors inde-
pendently associated with upper GI bleeding [109]. The
incidence of bleeding was 8.4% in the presence of these
two risk factors and only 0.1% in their absence [109].
Some years later, the same team in a randomized, multi-
center trial in 1,077 mechanically ventilated patients
compared two ulcer prophylactic drugs (ranitidine and
sucralfate) and identified a risk factor independent of
upper GI bleeding—peak creatinine (by 100 μmol/L
increments, OR 1.16; 95% CI 1.02-1.32)—and two pro-
tective factors—enteral feeding (OR 0.3; 95% CI 0.13-
0.67) and administration of ranitidine (OR 0.39; 95% CI
0.17-0.83) [111].
10. In children, a pediatric risk of mortality score
(PRISM) >10 associated with respiratory failure or
coagulopathy or both probably calls for ulcer
prophylaxis (strong agreement).
Pediatric data enabling analysis of the benefits of
prophylactic treatment of “stress ulcer” bleeding are rare
[112]. A 1998 prospective study in 881 children identi-
fied 3 risk factors independent of clinically significant
upper GI bleeding acquired in intensive care: respiratory
failure (OR 2.87; 95% CI 1.3-82.8). coagulopathy
(OR 9.3; 95% CI 2.8-30.3), and a pediatric risk of mortal-
ity score ≥10 (OR 13.4; 95% CI 3.7-47.9) [113]. Thepresence of two or more factors was associated with an
approximately 90% incidence of GI bleeding. This study
confirms other data identifying mechanical ventilation,
lung disorders, and thrombocytopenia as risk factors for
GI bleeding [114-116].
11. Screening for Helicobacter pylori should not be
routine in intensive care patients (strong agreement).
The prevalence of Helicobacter pylori infection in in-
tensive care is greater than that in a control population
[117]. However, there are few arguments to suggest that
Helicobacter pylori is responsible for upper GI bleeding
in intensive care. Three studies have reported a statis-
tical link between Helicobacter pylori infection and
stress-related GI bleeding [118-120]. Data from two of
them differ according to the tests used to diagnose
Helicobacter pylori infection [118,119]. By coupling sev-
eral diagnostic methods (serology, biopsy, enzyme im-
munoassay detection of antigen in stools), Maury et al.
found a significantly greater incidence of Helicobacter
pylori infection in the case of GI bleeding (36% vs. 16%)
[120]. However, this study was conducted in only 25
patients [120]. Lastly, three other studies found no cor-
relation between Helicobacter pylori infection and “stress
ulcer” bleeding [117,121,122].
12. A nasogastric tube should probably be removed
once it is no longer used (expert opinion,
strong agreement).
13. A large bore nasogastric tube for aspiration should
probably be replaced by a small-calibre enteral tube
as soon as possible (expert opinion, strong
agreement).
14. Antacids should not be used to prevent
“stress ulcer” bleeding (strong agreement).
15. H2 receptor antagonists and PPIs are probably
comparable but of low efficacy in preventing “stress
ulcer” bleeding (weak agreement).
16. H2 receptor antagonists and PPIs are probably
comparable regarding the risk ventilator-associated
pneumonia during mechanical ventilation
(strong agreement).
In the prevention of upper GI bleeding in intensive
care, H2 receptor antagonists, long used in clinical trials,
are superior to placebo [3,123], antacids [123], and su-
cralfate [124]. A recent meta-analysis showed that H2 re-
ceptor antagonist treatment was associated with a
significant reduction in the risk of GI bleeding compared
with placebo (OR 0.47; 95% CI 0.29-0.76) [3]. In contrast,
this risk decrease was not observed in the subgroup of ent-
erally fed patients (OR 1.26; 95% CI 0.43-3.7) [3]. PPIs have
not been compared with placebo in this indication. A
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lated patients compared a PPI (oral omeprazole) and an H2
receptor antagonist (intravenous cimetidine) in prophylaxis
of upper GI bleeding in intensive care [125]. The time spent
at pH ≥6 was significantly greater in the omeprazole group
than in the cimetidine group (100% vs. 50% per treatment
day), and the prevalence of GI bleeding did not differ be-
tween the two groups. A recent meta-analysis comparing
PPIs and H2 receptor antagonists confirmed this result
[126] and also showed that there was no difference between
PPIs and H2 receptor antagonists in terms of the risk of
nosocomial pneumonia [126].
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